在乳腺缩小患者中使用植物性可吸收的血静粉和静脉注射的特兰克萨姆酸可以降低血瘤的发生率
Anjali Om1, Bo Hyun Kong2, Orr Shauly2
1From the Division of Plastic and Reconstructive Surgery, Emory University.
Annals of plastic surgery
|December 12, 2025
概括
静脉注射的松酸 (TXA) 在减小乳腺造形术后显著减少了血液瘤. 添加Arista提供了一个小额额外的好处,特别是对于不能使用TXA的患者.
科学领域:
- 整形外科 整形外科 整形外科
- 手术瘤学手术瘤学
- 伤口愈合 治愈 伤口愈合
背景情况:
- 降低乳房整形术有效治疗症状性巨,但会带来血瘤和感染等并发症的风险.
- 众所周知,胺酸 (TXA) 在各种手术中可以减少失血和血液瘤.
- 在乳腺外科手术中,像Arista这样的局部药物的有效性尚未得到充分证实.
研究的目的:
- 评估静脉注射的松酸 (TXA) 和局部阿里斯塔在减少减小乳房整形术后术后并发症的联合作用.
- 为了比较单独TXA的疗效,Arista加TXA,和没有治疗治疗手术部位并发症的管理.
主要方法:
- 一项回顾性队列研究包括464名接受双边减少乳房整形手术的患者.
- 患者被分为三个组:TXA + Arista (n=120),单独使用TXA (n=133) 和对照组 (n=211).
- 主要结局是血瘤发生率;次要结局包括血清瘤,感染和伤口愈合延迟.
主要成果:
- 与单独TXA (3.8%) 和对照组 (10.0%) 相比,TXA和Arista的组合显示出最低的总血液瘤发生率 (2.5%).
- 感染率在TXA+Arista组 (0.8%) 与单独TXA (6.8%) 和对照组 (2.8%) 相比明显较低.
- 与单独使用TXA (16.5%) 和对照 (11.4%) 相比,联合治疗 (1.7%) 也显著减少了伤口愈合的延迟.
结论:
- 静脉注射TXA在减小乳腺整形术后有效地减少了血液瘤.
- 添加局部阿里斯塔在减少血液瘤和感染方面提供了适度的额外好处.
- 对于无法接受TXA的患者来说,Arista可能是一个有用的替代品,需要进一步调查.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
01:30Venous Thrombosis IV: Nursing Management
182
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
182
01:05Introduction to Hemostasis
13.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K